Methods and compositions concerning poxviruses and cancer
CA 2818693 C · Owner: Sillajen Biotherapeutics, Inc. · Inventors: Kirn, David; Thorne, Steve H.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention concerns methods and compositions for the treatment of cancer and cancer cells using altered poxviruses including a vaccinia virus that has been altered to generate a more effective therapeutic agent. Such poxviruses are engineered to be attenuated or weakened in their ability to affect normal cells. In some embodiments methods and compositions involve poxviruses that possess mutations that result in poxviruses with diminished or eliminated capability to implement an antiviral response in a host. Poxviruses with these mutations in combination with other mutations can be employed for more effective treatment of cancer.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 11, 2003 and granted May 17, 2016. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 11, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 11, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.